- Boston Scientific Corporation (NYSE:BSX) is expected to report a 12.7% increase in EPS and an 18% rise in revenue for the upcoming quarter.
- Despite a slight downward revision in EPS estimates, the company has a history of exceeding earnings expectations.
- Financial metrics reveal a P/E ratio of 59.41 and a debt-to-equity ratio of 0.54, indicating moderate debt levels and reasonable liquidity.
Boston Scientific Corporation, listed on the NYSE under the symbol BSX, is a prominent player in the medical device industry. The company specializes in developing and manufacturing a wide range of products for interventional medical specialties, including cardiovascular and MedSurg sectors. Key innovations like the WATCHMAN FLX Pro and AGENT DCB have bolstered its market position.
On October 22, 2025, NYSE:BSX is set to release its quarterly earnings, with Wall Street estimating an earnings per share (EPS) of $0.71. This represents a 12.7% increase from the previous year, highlighting the company’s growth trajectory. Revenue is projected to reach approximately $4.97 billion, marking an 18% rise compared to the same period last year.
Despite the positive outlook, there has been a slight downward revision of 0.2% in the consensus EPS estimate over the past 30 days. This adjustment suggests that analysts have recently reevaluated their forecasts, which can significantly influence investor reactions and short-term stock price movements.
Boston Scientific has a history of exceeding earnings expectations, with an average surprise of 8.11% over the past four quarters. In the last reported quarter, the company achieved an EPS of $0.75, surpassing the Zacks Consensus Estimate by 4.17%. However, the stock’s movement will largely depend on how the actual results compare to these expectations.
The company’s financial metrics, such as a price-to-earnings (P/E) ratio of approximately 59.41 and a debt-to-equity ratio of 0.54, indicate a moderate level of debt relative to equity. Additionally, a current ratio of about 1.37 suggests that Boston Scientific has a reasonable level of liquidity to cover its short-term liabilities.
